Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT00052390
Phase
PHASE2
Status
Completed

Conditions

  • Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • doxorubicin hydrochloride — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. Combining doxorubicin with bevacizumab may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin with bevacizumab in treating patients who have locally recurrent or metastatic soft tissue sarcoma.

Key Dates

First listed
Jan 27, 2003
Start date
Oct 31, 2002
Status verified
Feb 2004
Completion
Oct 31, 2005

Study Design

Primary purpose
TREATMENT

Locations (3)

FacilityCityStateZIPSite coordinators
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer InstituteBostonMassachusetts02115-
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10021-
Huntsman Cancer InstituteSalt Lake CityUtah84112-

Find similar trials in Boston, MA

By research site
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute· Boston, MAMemorial Sloan-Kettering Cancer Center· New York, NYHuntsman Cancer Institute· Salt Lake City, UT

Related Studies